Larazotide

Phase II Trials

Also known as: Larazotide Acetate, AT-1001, INN-202

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Larazotide is a synthetic octapeptide that acts as a tight junction regulator in gut epithelium. Research has examined its potential to reduce intestinal permeability ('leaky gut') in celiac disease and other inflammatory gut conditions by antagonizing the zonulin pathway.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

Immune Support
Gut & GI Health

Mechanism of Action

Larazotide acts as a zonulin receptor antagonist, preventing zonulin from opening tight junctions between intestinal epithelial cells. Research in celiac disease models shows it can reduce antigen translocation across the gut barrier, potentially decreasing systemic inflammatory responses.

Safety Notes

Phase IIb/III clinical trials in celiac disease showed a favorable safety profile with minimal systemic absorption. Not FDA-approved. Primarily acts locally in the gut lumen.

Want to learn more?

Ask Research Chat about Larazotide

Research Profile

Half-Life

Not well established (minimal systemic absorption)

Administration

oral

Legal Status (US)

Investigational drug. Research chemical. Not FDA-approved.

42 indexed research passages

Related Peptides

Tropisetron

Tropisetron is a 5-HT3 receptor antagonist and alpha7 nicotinic acetylcholine receptor agonist approved in various countries for chemotherapy-induced nausea. Research has also examined its potential roles in pain management, fibromyalgia, and cognitive enhancement through its dual receptor pharmacology.

KPV

KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Research has examined its potent anti-inflammatory properties, particularly in gut epithelial models and inflammatory bowel disease research.

LL-37

LL-37 is the only known human cathelicidin antimicrobial peptide, derived from the C-terminal cleavage of hCAP18 and produced primarily by epithelial cells, neutrophils, and macrophages. Research has examined its roles in innate immune defense, wound healing, angiogenesis promotion, and modulation of inflammatory responses, as well as its potential as a therapeutic agent.

Roxadustat

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in multiple countries including China, Japan, and the EU for the management of anemia associated with chronic kidney disease. It stimulates endogenous erythropoietin production by stabilizing HIF-alpha proteins.